CureVac Acquisition Nears Critical Shareholder Vote

CureVac NL0015436031

The proposed multi-billion euro acquisition of CureVac by BioNTech enters its final phase with two crucial November deadlines approaching. Shareholders face a pivotal decision that could see the Tübingen-based biotech firm become a permanent component of the mRNA giant.

BioNTech moved to reassure CureVac investors regarding its financial capability to complete the acquisition through a recent SEC filing. Submitted on November 12, this supplemental prospectus reveals BioNTech generated €1.96 billion in revenue during the first nine months of 2025 while reporting a net loss of €831 million. Despite this loss, the Mainz-based company maintains substantial liquidity with €16.7 billion available in cash and marketable securities.